文献速递甲状腺疾病

BRAFV600E转导SV40永生化正常人甲状腺细胞系在小鼠异种移植模型中诱导去分化甲状腺癌发生

BRAFV600E Transduction of an SV40-Immortalized Normal Human Thyroid Cell Line Induces Dedifferentiated Thyroid Carcinogenesis in a Mouse Xenograft Model.
PubMed 文献 · Thyroid · 2020-01-01

研究将SV40永生化正常人甲状腺细胞系Nthy-ori 3-1分别转导BRAFWT(Nthy/WT)或BRAFV600E(Nthy/V600E)后皮下注射至NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ小鼠。Nthy/WT体内不致瘤,Nthy/V600E在4周内平均形成2784.343 mm3肿瘤,病理为去分化甲状腺癌,伴肺、肝及相关淋巴结转移。RNA测序显示突变型与野生型间5512个差异表达基因,与未分化甲状腺癌共享的差异基因多于乳头状甲状腺癌;PLX-4032(维莫非尼)显著抑制肿瘤生长和转移。

要点

  • Nthy/V600E在4周内平均形成2784.343 mm3肿瘤,病理为去分化甲状腺癌。
  • Nthy/V600E肿瘤出现肺、肝及相关淋巴结转移。
  • 突变型与野生型间5512个差异表达基因;PLX-4032显著抑制肿瘤生长和转移。

核心结论

  • BRAFV600E在SV40转染永生化正常人甲状腺细胞系的致癌转化中起关键作用。
  • 该异种移植模型预期有助于高度恶性甲状腺癌的病因与治疗研究。

研究设计与样本

  • 将表达BRAFWT(Nthy/WT)或BRAFV600E(Nthy/V600E)的慢病毒载体转导SV40永生化人甲状腺细胞系Nthy-ori 3-1。
  • 各细胞系皮下注射至NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ小鼠并进行病理分析。
  • 使用BRAFV600E选择性抑制剂PLX-4032(维莫非尼)验证突变效应;RNA测序分析转录组并与癌症细胞系百科全书及基因表达综合数据库数据比较。

主要发现

  • Nthy/WT在体内不致瘤,Nthy/V600E在4周内平均形成2784.343 mm3肿瘤。
  • 病理分析显示Nthy/V600E肿瘤为去分化甲状腺癌,并在肺、肝及相关淋巴结发现转移。
  • 转录组分析显示突变型与野生型细胞系间有5512个差异表达基因,与未分化甲状腺癌共享的差异基因多于乳头状甲状腺癌。
  • BRAFV600E主要通过调控G1/S期激活细胞周期。
  • PLX-4032治疗显著抑制肿瘤生长和转移。

临床怎么用

  • 作者认为该异种移植模型预期有助于高度恶性甲状腺癌的病因与治疗研究。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Background: Despite active studies of the clinical importance of BRAFV600E, suitable research models to investigate the role of this mutation in the etiopathogenesis of human thyroid cancers are limited. Thus, we generated cell lines by transducing the simian virus (SV)-40 immortalized human thyroid cell line Nthy-ori 3-1 (Nthy) with lentiviral vectors expressing either BRAFWT (Nthy/WT) or BRAFV600E. Nthy/WT and Nthy/V600E cells were then xenografted into mice to evaluate the carcinogenic role of BRAFV600E. Methods: Each cell line was subcutaneously injected into NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ mice, and a pathological analysis was performed. The effects of the mutation were further verified by using a BRAFV600E-selective inhibitor (PLX-4032, vemurafenib). The transcriptome was analyzed by RNA sequencing and compared with data from The Cancer Cell Line Encyclopedia and Gene Expression Omnibus. Results: While Nthy/WT was not tumorigenic in vivo, Nthy/V600E formed tumors reaching 2784.343 mm3 in 4 weeks, on average. A pathological analysis indicated that Nthy/V600E tumors were dedifferentiated thyroid cancer. We found metastases in the lung, liver, and relevant lymph nodes. A transcriptomic analysis revealed 5512 differentially expressed genes (DEGs) between the mutant and wild-type cell lines, and more DEGs were shared with anaplastic thyroid cancer than with papillary thyroid cancer. BRAFV600E activated the cell cycle mainly by regulating G1/S phases. PLX-4032 treatment significantly inhibited tumor growth and metastasis. Conclusions: Our data show that BRAFV600E plays a pivotal role in the carcinogenic transformation of an SV40-transfected immortalized normal human thyroid cell line. This xenograft model is expected to contribute to studies of the etiopathogenesis and treatment of highly malignant thyroid cancers.

来源:Thyroid,查看原文。版权归原作者所有。

引用

  1. Kim M, Kim SJ, Xu Z, et al. BRAFV600E Transduction of an SV40-Immortalized Normal Human Thyroid Cell Line Induces Dedifferentiated Thyroid Carcinogenesis in a Mouse Xenograft Model. Thyroid. 2020. PMID: 32122255. doi:10.1089/thy.2019.0301

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。